| Symbol | SNDX |
|---|---|
| Name | SYNDAX PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 730 THIRD AVENUE, NEW YORK, NY 10017 |
| Telephone | 781-419-1400 |
| Fax | — |
| — | |
| Website | https://www.syndax.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001395937 |
| Description | Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The companys product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the bodys immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Additional info from NASDAQ: |
2026-07-01 20:01
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Read more
2026-06-12 21:09
Botwood Nicholas A.J. 🟡 adjusted position in 42.0K shares (2 derivative) of Syndax Pharmaceuticals Inc (SNDX) at $18.14 ($2.7M) Transaction Date: Jun 11, 2026 | Filing ID: 269694
Read more
2026-06-12 20:10
📋 Botwood Nicholas A.J. (Officer) plans to sell 31K shares of Syndax Pharmaceuticals Inc (at $18.14 each, total $567K) Filed: Jun 12, 2026 | ID: 004618
Read more
2026-06-11 20:12
📋 Botwood Nicholas A.J. (Officer) plans to sell 34K shares of Syndax Pharmaceuticals Inc (at $17.78 each, total $609K) Filed: Jun 11, 2026 | ID: 004566
Read more
2026-06-11 11:03
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Read more
2026-06-10 20:15
(99% Neutral) SYNDAX PHARMACEUTICALS INC (SNDX) Announces Executive Changes
Read more
2026-06-04 11:16
(99% Neutral) SYNDAX PHARMACEUTICALS INC (SNDX) Provides Update on placement for general corporate purposes
Read more
2026-06-04 11:00
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
Read more
2026-06-04 09:37
New Form DEFA14A - Syndax Pharmaceuticals Inc <b>Filed:</b> 2026-06-04 <b>AccNo:</b> 0001193125-26-256557 <b>Size:</b> 276 KB
Read more
2026-06-02 20:30
Metzger Michael A 🔴 sold 6.8K shares of Syndax Pharmaceuticals Inc (SNDX) at $18.99 Transaction Date: Jun 01, 2026 | Filing ID: 253601
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05918913 | Expanded Access Program for Revumenib | — | Relapsed/Refractory Acute Leukemia | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07563010 | Menin-Inhibitor Targeted Maintenance in AML | Phase2 | Relapsed Adult AML | Not_Yet_Recruiting | 2026-12-01 | 2031-06-01 | ClinicalTrials.gov |
| NCT07212023 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnose… | Phase2 | Acute Myeloid Leukemia | Not_Yet_Recruiting | 2025-12-01 | 2031-04-01 | ClinicalTrials.gov |
| NCT07211958 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnose… | Phase3 | Acute Myeloid Leukemias | Recruiting | 2025-11-25 | 2031-01-01 | ClinicalTrials.gov |
| NCT06313437 | Revumenib in Combination With 7+3 + Midostaurin in AML | Phase1 | Acute Myeloid Leukemia | Recruiting | 2024-12-06 | 2028-03-02 | ClinicalTrials.gov |
| NCT06284486 | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhi… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2024-09-23 | 2028-12-30 | ClinicalTrials.gov |
| NCT06229912 | A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With U… | Phase2 | Leukemia | Recruiting | 2024-06-04 | 2028-12-01 | ClinicalTrials.gov |
| NCT06226571 | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants… | Phase1 | Acute Myeloid Leukemias | Active_Not_Recruiting | 2024-05-21 | 2027-02-01 | ClinicalTrials.gov |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Pa… | Phase1 | Refractory Acute Myeloid Leukemia | Recruiting | 2024-04-19 | 2027-04-01 | ClinicalTrials.gov |
| NCT06132256 | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary… | Phase2 | Idiopathic Pulmonary Fibrosis | Active_Not_Recruiting | 2023-12-11 | 2026-11-01 | ClinicalTrials.gov |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid … | Phase1 | Colorectal Cancer | Terminated | 2023-04-04 | 2025-06-30 | ClinicalTrials.gov |
| NCT05360160 | A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibito… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2022-10-14 | 2026-12-01 | ClinicalTrials.gov |
| NCT05406817 | Study of Radiolabeled Revumenib in Adults With Acute Leukemia | Phase1 | Acute Leukemia | Completed | 2022-08-05 | 2024-11-18 | ClinicalTrials.gov |
| NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R … | Phase1 | Relapsed/Refractory Leukemias | Completed | 2022-03-09 | 2024-07-29 | ClinicalTrials.gov |
| NCT04301778 | Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients Wit… | Phase2 | Unresectable Intrahepatic Cholangiocarcinoma | Completed | 2021-08-24 | 2024-02-06 | ClinicalTrials.gov |
| NCT04710576 | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft V… | Phase2 | Chronic Graft-versus-host-disease | Recruiting | 2021-03-04 | 2027-09-01 | ClinicalTrials.gov |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | Phase1 | Pancreas Cancer | Withdrawn | 2021-01-01 | 2022-11-01 | ClinicalTrials.gov |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resist… | Phase1 | Fallopian Tube Cancer | Terminated | 2020-10-01 | 2022-02-04 | ClinicalTrials.gov |
| NCT03978624 | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladd… | Phase2 | Bladder Cancer | Active_Not_Recruiting | 2020-09-23 | 2026-11-22 | ClinicalTrials.gov |
| NCT04415073 | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respi… | Phase2 | Coronavirus | Terminated | 2020-05-30 | 2020-07-13 | ClinicalTrials.gov |
| NCT04065399 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Re… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2019-11-05 | 2027-12-15 | ClinicalTrials.gov |
| NCT03765229 | An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III… | Phase2 | Melanoma | Completed | 2019-03-22 | 2023-07-31 | ClinicalTrials.gov |
| NCT03473639 | A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk B… | Phase1 | Metastatic Breast Cancer | Completed | 2019-01-29 | 2022-11-01 | ClinicalTrials.gov |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stag… | Early_Phase1 | Breast Cancer | Terminated | 2018-11-28 | 2019-10-11 | ClinicalTrials.gov |
| NCT03604692 | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD | Phase1 | Chronic Graft-versus-host-disease | Completed | 2018-11-01 | 2024-10-18 | ClinicalTrials.gov |
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | Phase2 | Renal Cell Carcinoma | Active_Not_Recruiting | 2018-05-24 | 2024-04-01 | ClinicalTrials.gov |
| NCT02697630 | Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of… | Phase2 | Metastatic Uveal Melanoma | Completed | 2018-02-21 | 2023-01-31 | ClinicalTrials.gov |
| NCT03238027 | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalum… | Phase1 | Solid Tumor | Completed | 2017-09-01 | 2020-11-20 | ClinicalTrials.gov |
| NCT03192111 | A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With N… | Phase1 | Renal Impairment | Completed | 2017-07-27 | 2017-11-23 | ClinicalTrials.gov |
| NCT03024437 | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Ad… | Phase1 | Metastatic Cancer | Terminated | 2017-06-29 | 2024-06-24 | ClinicalTrials.gov |
| NCT03179930 | Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractor… | Phase2 | Lymphoma | Active_Not_Recruiting | 2017-06-07 | 2026-06-01 | ClinicalTrials.gov |
| NCT03187015 | A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subj… | Phase1 | Drug Interaction | Completed | 2017-05-23 | 2017-08-22 | ClinicalTrials.gov |
| NCT02915523 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epit… | Phase1 | Epithelial Ovarian Cancer | Completed | 2016-12-19 | 2021-04-21 | ClinicalTrials.gov |
| NCT02922933 | A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage… | Phase1 | Volunteers | Completed | 2016-10-25 | 2017-05-08 | ClinicalTrials.gov |
| NCT02922946 | Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics o… | Phase1 | Volunteers | Completed | 2016-10-11 | 2017-06-26 | ClinicalTrials.gov |
| NCT02909452 | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients … | Phase1 | Neoplasms | Completed | 2016-09-20 | 2021-02-09 | ClinicalTrials.gov |
| NCT02897778 | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | Phase1 | Neoplasms | Completed | 2016-08-24 | 2017-03-13 | ClinicalTrials.gov |
| NCT02820961 | Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Wome… | Phase1 | Breast Cancer | Completed | 2016-06-29 | 2021-07-12 | ClinicalTrials.gov |
| NCT02708680 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Br… | Phase1 | Breast Cancer | Completed | 2016-05-01 | 2021-03-31 | ClinicalTrials.gov |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell… | Phase1 | Non-Small Cell Lung Cancer | Completed | 2015-08-26 | 2022-09-29 | ClinicalTrials.gov |
| NCT02115594 | Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Wome… | Phase2 | Breast Cancer | Withdrawn | 2014-04-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01594398 | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With … | Phase1 | Lung Cancer | Completed | 2012-05-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can … | Phase2 | Estrogen Receptor-negative Breast Cancer | Terminated | 2010-10-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT00866333 | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed … | Phase2 | Hodgkin's Lymphoma | Terminated | 2009-04-13 | 2013-02-08 | ClinicalTrials.gov |
| NCT00828854 | Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aroma… | Phase2 | ER+ Breast Cancer | Completed | 2008-10-01 | 2009-11-24 | ClinicalTrials.gov |
| NCT00750698 | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-… | Phase2 | Non Small Cell Lung Cancer | Terminated | 2008-08-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00676663 | Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatmen… | Phase2 | Breast Cancer | Completed | 2008-06-13 | 2012-11-26 | ClinicalTrials.gov |
| NCT00754312 | A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expressi… | Phase1 | Breast Cancer | Terminated | 2008-06-01 | 2009-02-28 | ClinicalTrials.gov |
| NCT00602030 | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatm… | Phase1 | Non-Small-Cell Lung Carcinoma | Completed | 2008-01-08 | 2012-02-01 | ClinicalTrials.gov |
Total clinical trials: 49
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Chemotherapy | Drug | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT05731947 |
| Revumenib | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT05731947 |
| HiDAC | Other | Phase PHASE1 | Acute Myeloid Leukemias | ACTIVE_NOT_RECRUITING | NCT06226571 |
| Chemotherapy Regimen | Drug | Phase PHASE1 | Acute Myeloid Leukemias | ACTIVE_NOT_RECRUITING | NCT06226571 |
| SNDX-5613 | Other | Phase PHASE1 | Acute Myeloid Leukemias | ACTIVE_NOT_RECRUITING | NCT06226571 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft-versus-host-disease | RECRUITING | NCT04710576 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Blinatumomab | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Revumenib | Other | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| FOLFOX regimen | Other | Phase PHASE1 | Pancreas Cancer | WITHDRAWN | NCT03760614 |
| Entinostat | Other | Phase PHASE1 | Pancreas Cancer | WITHDRAWN | NCT03760614 |
| Olaparib | Other | Phase PHASE1 | Fallopian Tube Cancer | TERMINATED | NCT03924245 |
| Entinostat | Other | Phase PHASE1 | Fallopian Tube Cancer | TERMINATED | NCT03924245 |
| Placebo | Other | Phase PHASE2 | Breast Cancer | WITHDRAWN | NCT02115594 |
| Entinostat | Other | Phase PHASE2 | Breast Cancer | WITHDRAWN | NCT02115594 |
| Fulvestrant | Other | Phase PHASE2 | Breast Cancer | WITHDRAWN | NCT02115594 |
| Entinostat | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT03192111 |
| Midazolam | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03187015 |
| Entinostat | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03187015 |
| Entinostat | Other | Phase PHASE1 | Volunteers | COMPLETED | NCT02922946 |
| Famotidine | Other | Phase PHASE1 | Volunteers | COMPLETED | NCT02922933 |
| Omeprazole | Other | Phase PHASE1 | Volunteers | COMPLETED | NCT02922933 |
| entinostat | Other | Phase PHASE1 | Volunteers | COMPLETED | NCT02922933 |
| Exemestane | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT01594398 |
| Erlotinib | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT01594398 |
| entinostat | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT01594398 |
| exemestane | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02820961 |
| entinostat | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02820961 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02909452 |
| Entinostat | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02909452 |
| Placebo | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02897778 |
| Entinostat | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02897778 |
| therapeutic conventional surgery | Procedure | Phase PHASE2 | Estrogen Receptor-negative Breast Cancer | TERMINATED | NCT01234532 |
| diagnostic laboratory biomarker analysis | Other | Phase PHASE2 | Estrogen Receptor-negative Breast Cancer | TERMINATED | NCT01234532 |
| anastrozole | Other | Phase PHASE2 | Estrogen Receptor-negative Breast Cancer | TERMINATED | NCT01234532 |
| entinostat | Other | Phase PHASE2 | Estrogen Receptor-negative Breast Cancer | TERMINATED | NCT01234532 |
| Placebo | Other | Phase PHASE2 | Coronavirus | TERMINATED | NCT04415073 |
| SNDX-6352 | Other | Phase PHASE2 | Coronavirus | TERMINATED | NCT04415073 |
| Capecitabine | Other | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT03473639 |
| Entinostat | Other | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT03473639 |
| Interleukin-2 | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03501381 |
| Entinostat | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03501381 |
| Entinostat | Other | Phase PHASE2 | Metastatic Uveal Melanoma | COMPLETED | NCT02697630 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Uveal Melanoma | COMPLETED | NCT02697630 |
| Pembrolizumab | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT03765229 |
| Entinostat | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT03765229 |
| Placebo | Other | Phase PHASE1 | Epithelial Ovarian Cancer | COMPLETED | NCT02915523 |
| avelumab | Other | Phase PHASE1 | Epithelial Ovarian Cancer | COMPLETED | NCT02915523 |
| entinostat | Other | Phase PHASE1 | Epithelial Ovarian Cancer | COMPLETED | NCT02915523 |
| Entinostat | Other | Phase EARLY_PHASE1 | Breast Cancer | TERMINATED | NCT03361800 |
| Durvalumab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03238027 |
| Axatilimab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03238027 |
| Chemotherapy Regimen 2 | Drug | Phase PHASE1 | Relapsed/Refractory Leukemias | COMPLETED | NCT05326516 |
| Chemotherapy Regimen 1 | Drug | Phase PHASE1 | Relapsed/Refractory Leukemias | COMPLETED | NCT05326516 |
| Revumenib | Other | Phase PHASE1 | Relapsed/Refractory Leukemias | COMPLETED | NCT05326516 |
| Placebo | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02708680 |
| Atezolizumab | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02708680 |
| Entinostat | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02708680 |
| Revumenib | Other | Phase PHASE1 | Acute Leukemia | COMPLETED | NCT05406817 |
| Entinostat | Other | Phase PHASE1 | Metastatic Cancer | TERMINATED | NCT03024437 |
| Bevacizumab | Other | Phase PHASE1 | Metastatic Cancer | TERMINATED | NCT03024437 |
| Atezolizumab | Other | Phase PHASE1 | Metastatic Cancer | TERMINATED | NCT03024437 |
| pembrolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT02437136 |
| entinostat | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT02437136 |
| Pembrolizumab | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT03179930 |
| Entinostat | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT03179930 |
| Revumenib | Other | Preclinical | Relapsed/Refractory Acute Leukemia | NO_LONGER_AVAILABLE | NCT05918913 |
| axatilimab | Other | Phase PHASE1 | Chronic Graft-versus-host-disease | COMPLETED | NCT03604692 |
| Procedure/Surgery | Procedure | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03978624 |
| Entinostat | Other | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03978624 |
| Pembrolizumab | Other | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03978624 |
| Chemotherapy | Drug | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT05731947 |
| Revumenib | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT05731947 |
| HiDAC | Other | Phase PHASE1 | Acute Myeloid Leukemias | RECRUITING | NCT06226571 |
| Chemotherapy Regimen | Drug | Phase PHASE1 | Acute Myeloid Leukemias | RECRUITING | NCT06226571 |
| SNDX-5613 | Other | Phase PHASE1 | Acute Myeloid Leukemias | RECRUITING | NCT06226571 |
| Revumenib | Other | Phase PHASE2 | Leukemia | RECRUITING | NCT06229912 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| intrathecal (IT) chemotherapy | Drug | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Revumenib | Other | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| SNDX-6352 | Other | Phase PHASE2 | Unresectable Intrahepatic Cholangiocarcinoma | COMPLETED | NCT04301778 |
| Durvalumab | Other | Phase PHASE2 | Unresectable Intrahepatic Cholangiocarcinoma | COMPLETED | NCT04301778 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft-versus-host-disease | ACTIVE_NOT_RECRUITING | NCT04710576 |
| cobicistat | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT04065399 |
| revumenib | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT04065399 |
| Intensive Chemotherapy Regimen | Drug | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Revumenib | Other | Phase PHASE3 | Acute Myeloid Leukemias | RECRUITING | NCT07211958 |
| Daunorubicin | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06313437 |
| Cytarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06313437 |
| Midostaurin | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06313437 |
| Revumenib | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06313437 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | ACTIVE_NOT_RECRUITING | NCT06132256 |
| Axatilimab | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | ACTIVE_NOT_RECRUITING | NCT06132256 |
| Revumenib | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06284486 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06284486 |
| ASTX727 | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05360160 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05360160 |
| SNDX-5613 | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05360160 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Placebo | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Revumenib | Other | Phase PHASE2 | Relapsed Adult AML | NOT_YET_RECRUITING | NCT07563010 |
| Blinatumomab | DRUG | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| Intensive Chemotherapy Regimen | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT07212023 |
| Daunorubicin | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06313437 |
| Midostaurin | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06313437 |
| HiDAC | DRUG | Phase PHASE1 | Acute Myeloid Leukemias | RECRUITING | NCT06226571 |
| Chemotherapy Regimen | DRUG | Phase PHASE1 | Acute Myeloid Leukemias | RECRUITING | NCT06226571 |
| SNDX-5613 | DRUG | Phase PHASE1 | Acute Myeloid Leukemias | RECRUITING | NCT06226571 |
| Methotrexate | DRUG | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Cytarabine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06313437 |
| intrathecal (IT) chemotherapy | DRUG | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Azacitidine | DRUG | Phase PHASE1 | Refractory Acute Myeloid Leukemia | RECRUITING | NCT06177067 |
| Venetoclax | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06284486 |
| Chemotherapy | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT05731947 |
| Chemotherapy Regimen 2 | DRUG | Phase PHASE1 | Relapsed/Refractory Leukemias | COMPLETED | NCT05326516 |
| Chemotherapy Regimen 1 | DRUG | Phase PHASE1 | Relapsed/Refractory Leukemias | COMPLETED | NCT05326516 |
| Revumenib | DRUG | Phase PHASE1 | Blinatumomab | NOT_YET_RECRUITING | NCT07283640 |
| SNDX-6352 | DRUG | Phase PHASE2 | Coronavirus | TERMINATED | NCT04415073 |
| cobicistat | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT04065399 |
| revumenib | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT04065399 |
| Procedure/Surgery | PROCEDURE | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03978624 |
| Olaparib | DRUG | Phase PHASE1 | Fallopian Tube Cancer | TERMINATED | NCT03924245 |
| FOLFOX regimen | DRUG | Phase PHASE1 | Pancreas Cancer | WITHDRAWN | NCT03760614 |
| axatilimab | DRUG | Phase PHASE1 | Chronic Graft-versus-host-disease | COMPLETED | NCT03604692 |
| Interleukin-2 | DRUG | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03501381 |
| Capecitabine | DRUG | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT03473639 |
| Durvalumab | DRUG | Phase PHASE2 | Unresectable Intrahepatic Cholangiocarcinoma | COMPLETED | NCT04301778 |
| Axatilimab | DRUG | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | ACTIVE_NOT_RECRUITING | NCT06132256 |
| Midazolam | DRUG | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03187015 |
| Bevacizumab | DRUG | Phase PHASE1 | Metastatic Cancer | TERMINATED | NCT03024437 |
| avelumab | DRUG | Phase PHASE1 | Epithelial Ovarian Cancer | COMPLETED | NCT02915523 |
| Atezolizumab | DRUG | Phase PHASE1 | Metastatic Cancer | TERMINATED | NCT03024437 |
| Pembrolizumab | DRUG | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03978624 |
| pembrolizumab | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT02437136 |
| Fulvestrant | DRUG | Phase PHASE2 | Breast Cancer | WITHDRAWN | NCT02115594 |
| Exemestane | DRUG | Phase PHASE1 | Lung Cancer | COMPLETED | NCT01594398 |
| therapeutic conventional surgery | PROCEDURE | Phase PHASE2 | Estrogen Receptor-negative Breast Cancer | TERMINATED | NCT01234532 |
| diagnostic laboratory biomarker analysis | OTHER | Phase PHASE2 | Estrogen Receptor-negative Breast Cancer | TERMINATED | NCT01234532 |
| anastrozole | DRUG | Phase PHASE2 | Estrogen Receptor-negative Breast Cancer | TERMINATED | NCT01234532 |
| Aromatase Inhibitor (AI) Therapy | DRUG | Phase PHASE2 | ER+ Breast Cancer | COMPLETED | NCT00828854 |
| SNDX-275 | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT00754312 |
| exemestane | DRUG | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02820961 |
| entinostat | DRUG | Phase PHASE1 | Volunteers | COMPLETED | NCT02922933 |
| Erlotinib | DRUG | Phase PHASE1 | Lung Cancer | COMPLETED | NCT01594398 |
| Placebo | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT07212023 |
| Entinostat | DRUG | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03978624 |
Total products: 348